Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate the Efficacy of Allogeneic Human Cord Blood-derived Mesenchymal Stromal Cells in Maintaining Remission After Immunosuppressive Therapy Withdrawal in Pediatric Patients With Steroid-dependent Nephrotic Syndrome

NCT04034316 is registered in ClinicalTrials.gov with Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico as lead sponsor.

NCT NCT04034316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04034316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate the Efficacy of Allogeneic Human Cord Blood-derived Mesenchymal Stromal Cells in Maintaining Remission After Immunosuppressive Therapy Withdrawal in Pediatric Patients With Steroid-dependent Nephrotic Syndrome
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2018
Completion date
August 31, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic nephrotic syndrome, nephrotic syndrome in children, steroid-dependent nephrotic syndrome